Vijay Narendran
Hematology & Oncology · Palm Springs, FLNPI 1629395249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,508 and has fallen 86.4% since, to $340 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 253 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$715
- Medtronic$656
- Pfizer$438
- Seagen Inc.$367
- Genentech USA, Inc.$339
- Amgen$226
- plus $3K from 37 others
What the payments were for
- Food & beverage$4,96793%
- Education$3797%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 35 | $715 |
| Medtronic | 6 | $656 |
| Pfizer | 34 | $438 |
| Seagen Inc. | 15 | $367 |
| Genentech USA, Inc. | 16 | $339 |
| Amgen | 17 | $226 |
| Bristol Myers Squibb | 7 | $210 |
| E.r. Squibb & Sons, L.L.C. | 15 | $193 |
| Novartis | 10 | $176 |
| AstraZeneca(2 entities) | 13 | $167 |
| Sirtex Medical Inc | 1 | $143 |
| Sanofi | 7 | $125 |
| GSK | 1 | $125 |
| Merck | 7 | $114 |
| Astellas Pharma US Inc | 7 | $114 |
| Lilly USA, LLC | 7 | $110 |
| Incyte Corporation | 5 | $100 |
| Intuitive Surgical | 1 | $89 |
| AbbVie | 4 | $78 |
| Bayer | 4 | $78 |
| Eisai Inc. | 4 | $75 |
| Sobi, Inc | 3 | $72 |
| Tersera Therapeutics LLC | 2 | $63 |
| Dova Pharmaceuticals | 4 | $58 |
| Exelixis Inc. | 3 | $49 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $48 |
| Beigene USA, Inc. | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $37 |
| AMAG Pharmaceuticals, Inc. | 2 | $35 |
| Advanced Accelerator Applications | 2 | $33 |
| Tolmar Pharmaceuticals, Inc. | 2 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| Deciphera Pharmaceuticals Inc. | 1 | $26 |
| Foundation Medicine, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Clovis Oncology, Inc. | 1 | $21 |
| Aurobindo Pharma USA, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $18 |
| Legend Biotech USA Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,345 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 84 | $1,039,918 |
| RevlimidLenalidomide | 52 | $755,720 |
| BrukinsaZanubrutinib | 55 | $747,480 |
| SprycelDasatinib | 14 | $240,122 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 11 | $217,535 |
| NubeqaDarolutamide | 13 | $204,808 |
| DarzalexDaratumumab | 22 | $100,694 |
| VenclextaVenetoclax | 21 | $97,246 |
| EliquisApixaban | 35 | $20,046 |
| Imatinib Mesylate | 23 | $9,867 |
| Oxycodone Hcl | 39 | $1,049 |
| Irinotecan Hcl | 11 | $664 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $574 |
| CholestyramineCholestyramine (With Sugar) | 12 | $540 |
| Dexamethasone | 23 | $428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $210 | $755,72052 claims |
| Beigene USA, Inc.Brukinsa | $41 | $747,48055 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $193 | $240,12214 claims |
| BayerNubeqa | $78 | $204,80813 claims |
| Johnson & JohnsonDarzalex | $715 | $100,69422 claims |
| AbbVieVenclexta | $78 | $97,24621 claims |
| PfizerEliquis | $438 | $20,04635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Palm Springs
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.